for investors
Early Stage Investment.
An opportunity in a rapidly growing market.
The Trans-Duodenal Barrier developed by TDC is a patented endoscopic transduodenal bypass implant for combined diabetes/obesity therapy that atraumatically prevents nutrient absorption in the duodenum and delays gastric emptying.
The present prototype has successfully completed initial animal studies (ZIM-funded). Following successful CE certification, commercialization as a class IIb product is expected to start in 2027.
The Trans-Duodenal Barrier is a globally unique product for the pronounced growth market of obesity, DMT2 and NASH (approx. 800 million patients worldwide) and already has a sales potential in the billions at 0.1% penetration.
The uniqueness of the Trans-Duodenal Barrier is based in particular on the patented method of fixation and therefore also allows much broader use than previous methods for combining restrictive and malabsorptive principles of action.
Initial situation
60
million diabetes patients in the EU
26,1
million patients with fatty liver disease
81,3
million obesity patients
Strong upward trend
Treatment methods to date
Conservative therapy
- Ineffective because usually not effective in the long term
- “unpopular” because a very high personal contribution is required
- Medication: not yet successful despite immense investment in research
Surgical therapy
- Effective, but irreversible
- Lifelong aftercare, therefore expensive
- Unclear long-term consequences
- Fear-inducing
Trans-Duodenal Barrier
1
Implements experience from surgery: Malabsorptive procedures more effective than restrictive procedures alone
2
Simple implantation as part of an outpatient gastroscopy with i.v. sedaton (propofole)
3
No anesthesia, no X-ray fluoroscopy, no medication required
4
Proven efficacy in type 2 diabetes, probable efficacy in fatty liver and obesity
5
Reversible, repeatable, combinable
Roadmap
Q1/2023
Completion of prototype design
Q3/2024
Finalize design
Q2/2026
Start of clinical trial
Q4/2027
Completion of clinical study
Q1/2028
CE certification, preparation for global marketing & distribution
Q1–2/2028
Launch of 3 multicenter
PMCF studies
Development of global marketing & distribution
Q2/2030
Completion of Multicenter PMCF Studies